.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 4,297,360

« Back to Dashboard

Details for Patent: 4,297,360

Title: 5-(Pyridinyl)pyridine-2,3-diamines, preparation thereof and their cardiotonic use
Abstract:2-R.sub.3 RN-3-R.sub.1 R'N-5-PY-6-Q-pyridines (I) or pharmaceutically-acceptable acid-addition salts thereof are useful as intermediates in the preparation of 1- or 3-substituted-1,3-dihydro-5-Q-6-PY-2H-imidazo[4,5-b]pyridin-2-ones or -2-thiones and also as intermediates for preparing 1- or 3-substituted-5-Q-6-PY-3H(or 1H)-imidazo[4,5-b]pyridines, where R.sub.1, R.sub.3, R, R', PY and Q are defined hereinbelow. Also shown are processes for preparing I and the following intermediates used therein: 2-halo-3-nitro-5-PY-6-Q-pyridines (III), 2-R.sub.3 RN-3-nitro-5-PY-6-Q-pyridines (V), 2-halo-5-PY-6-Q-pyridines (VII), 2-R.sub.3 RN-5-PY-6-Q-pyridines (VIII) and 2-R.sub.3 RN-3-halo-5-PY-6-Q-pyridines (IX) or salts thereof. Certain embodiments of II and VIII also are useful as cardiotonics and are shown as active components of cardiac compositions and methods for increasing cardiac contractility.
Inventor(s): Lesher; George Y. (Schodack, NY), Opalka, Jr.; Chester J. (Schodack, NY), Page; Donald F. (East Greenbush, NY)
Assignee: Sterling Drug Inc. (New York, NY)
Filing Date:Mar 28, 1980
Application Number:06/135,100
Claims:1. A 2-R.sub.3 RN-3-R.sub.1 RN-5-PY-6-Q-pyridine having the formula ##STR4## or pharmaceutically-acceptable acid-addition salt thereof, where Q, R and R' are each hydrogen or lower-alkyl, PY is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two lower-alkyl substituents, and, R.sub.1 and R.sub.3 are each hydrogen, lower-alkyl, lower-hydroxyalkyl, 2,3-dihydroxypropyl, lower-alkoxyalkyl or Y-NB where Y is lower-alkylene having at least two carbon atoms between its connecting linkgages and NB is di-(lower-alkyl)amino or 4-morpholinyl.

2. A compound according to claim 1 where Q is hydrogen, methyl or ethyl.

3. A compound according to claim 1 where PY is 4-pyridinyl or 3-pyridinyl.

4. A compound according to claim 1 wherein R and R' are each hydrogen when one of R.sub.1 or R.sub.3 is hydrogen and the other of R.sub.1 or R.sub.3 is methyl, ethyl or 2-hydroxyethyl.

5. A compound according to claim 1 where R.sub.1 and R' are each hydrogen when R.sub.3 is methyl or ethyl and R is hydrogen, methyl or ethyl.

6. A 2-halo-3-nitro-5-PY-6-Q-pyridine or pharmaceutically-acceptable acid-addition salt thereof, where halo is bromo or chloro, Q is hydrogen or lower-alkyl and PY is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two lower-alkyl substituents.

7. A 2-R.sub.3 RN-3-nitro-5-PY-6-Q-pyridine or pharmaceutically-acceptable acid-addition salt thereof, where Q and R are each hydrogen or lower-alkyl, PY is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two lower-alkyl substituents and R.sub.3 is hydrogen, lower-alkyl, lower-hydroxyalkyl, 2,3-dihydroxypropyl, lower-alkoxyalkyl or Y-NB where Y is lower-alkylene having at least two carbon atoms between its connecting linkages and NB is di-(lower-alkyl)amino or 4-morpholinyl.

8. A 2-halo-5-PY-6-Q-pyridine or pharmaceutically-acceptable acid-addition salt thereof, where halo is bromo or chloro, Q is hydrogen or lower-alkyl, and PY is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two lower-alkyl substituents.

9. A 2-R.sub.3 RN-5-PY-6-Q-pyridine or pharmaceutically-acceptable acid-addition salt thereof, where R and Q are each lower-alkyl, PY is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two lower-alkyl substituents and R.sub.3 is hydrogen, lower-alkyl, lower-hydroxyalkyl, 2,3-dihydroxypropyl, lower-alkoxyalkyl or Y-NB where Y is lower-alkylene having at least two carbon atoms between its connecting linkages and NB is di-(lower-alkyl)amino or 4-morpholinyl.

10. A 2-R.sub.3 RN-3-halo-5-PY-6-Q-pyridine or pharmaceutically-acceptable acid-addition salt thereof, where R and Q are each hydrogen or lower-alkyl, halo is bromo, chloro or iodo, Py is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two lower-alkyl substituents and R.sub.3 is hydrogen, lower-alkyl, lower-hydroxyalkyl, 2,3-dihydroxypropyl, lower-alkoxyalkyl or Y-NB where Y is lower-alkylene having at least two carbon atoms between its connecting linkages and NB is di-(lower-alkyl)amino or 4-morpholinyl.

11. A cardiotonic composition for increasing cardiac contractility, said composition comprising a pharmaceutically-acceptable inert carrier and, as the active component thereof, an effective amount of a cardiotonic 2-NRR-3-NR'R'-5-PY-6-Q-pyridine or pharmaceutically-acceptable acid-addition salt thereof, where Q is hydrogen or lower-alkyl, PY is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two lower-alkyl substituents, and NRR and NR'R' are each amino, lower-alkylamino or di-(lower-alkyl)amino.

12. The method for increasing cardiac contractility in a patient requiring such treatment which comprises administering orally or parenterally in a solid or liquid dosage form to such patient an effective amount of a cardiotonic 2-NRR-3-NR'R'-5-PY-6-Q-pyridine or pharmaceutically-acceptable acid-addition salt thereof, where Q is hydrogen or lower-alkyl, PY is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two lower-alkyl substituents, and NRR and NR'R' are each amino, lower-alkylamino or di-(lower-alkyl)amino.

13. A cardiotonic composition for increasing cardiac contractility, said composition comprising a pharmaceutically-acceptable inert carrier and, as the active component thereof, an effective amount of a cardiotonic 2-amino(or monomethylamino or dimethylamino)-5-PY-6-Q-pyridine or pharmaceutically-acceptable acid-addition salt thereof, where Q is hydrogen or lower-alkyl, and PY is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two lower-alkyl substituents.

14. The method for increasing cardiac contractility in a patient requiring such treatment which comprises administering orally or parenterally in a solid or liquid dosage form to such patient an effective amount of a cardiotonic 2-amino(or monomethylamino or dimethylamino)-5-PY-6-Q-pyridine or pharmaceutically-acceptable acid-addition salt thereof, where Q is hydrogen or lower-alkyl and PY is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two lower-alkyl substituents.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc